Scarica l'app Stockscreener
3.44
1.18%
0.04
Dopo l'orario di chiusura:
3.31
-0.13
-3.78%
Precedente Chiudi:
$3.40
Aprire:
$3.45
Volume 24 ore:
16,534
Relative Volume:
0.02
Capitalizzazione di mercato:
$7.37M
Reddito:
$743.00K
Utile/perdita netta:
$-7.63M
Rapporto P/E:
-0.2763
EPS:
-12.4498
Flusso di cassa netto:
-
1 W Prestazione:
+5.85%
1M Prestazione:
+18.21%
6M Prestazione:
-48.81%
1 anno Prestazione:
-83.38%
Intervallo 1D:
$3.44
$3.545
Intervallo di 1 settimana:
$3.22
$3.60
Portata 52W:
$2.83
$23.40
Can-Fite Biopharma Ltd ADR Stock (CANF) Company Profile
Nome
Can-Fite Biopharma Ltd ADR
Settore
Industria
Telefono
972 3 924 1114
Indirizzo
10 Bareket Street, Kiryat Matalon PO Box 7537, Petah-Tikva
Compare CANF vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CANF
Can-Fite Biopharma Ltd ADR
|
3.44 | 7.28M | 743.00K | -7.63M | 0 | -12.45 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Can-Fite Biopharma Ltd ADR Stock (CANF) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2017-08-11 | Iniziato | Maxim Group | Buy |
| 2016-10-19 | Ripresa | ROTH Capital | Buy |
| 2016-08-29 | Ripresa | Rodman & Renshaw | Buy |
| 2015-11-30 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-31 | Reiterato | H.C. Wainwright | Buy |
| 2015-03-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2014-12-29 | Reiterato | ROTH Capital | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Can-Fite Biopharma Ltd ADR Borsa (CANF) Ultime notizie
CANF Stock Price, Quote & Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market - Sahm
CANF Stock Chart | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
What Can-Fite Bio (CANF) is doing that could pay off big later (Rallies Strongly) 2026-05-08Long Term Investing - newser.com
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months - ChartMill
CANF - Finviz
CANF Ownership | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can Fite Biopharma Ltd ADR (CANF) - Minichart
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - ChartMill
Can-Fite BioPharma (CANF) outlines clinical pipeline, cash runway and key risks - Stock Titan
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - ChartMill
Can-Fite reports 2025 loss, raises $4.3 million in March - Investing.com
CANF Earnings History & Surprises | EPS & Revenue Results | CAN FITE BIOPHARMA LTD-ADR (NYSEARCA:CANF) - ChartMill
Can-Fite receives Israeli patent for obesity treatment use - Investing.com
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - Sahm
12 Health Care Stocks Moving In Wednesday's After-Market Session - Sahm
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
Can-Fite BioPharma raises $4M through warrant exercise - Investing.com
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds - ChartMill
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy - ChartMill
Can Fite Biopharma stock rises after patient success with liver treatment - Investing.com
Can-Fite BioPharma schedules special shareholder meeting as NYSE American issues non-compliance notice - Investing.com
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson - Sahm
Published on: 2026-01-10 23:44:28 - ulpravda.ru
Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction - Investing.com
Can Fite Biopharma stock soars on Brazil patent grant for sexual dysfunction By Investing.com - Investing.com South Africa
Traders are paying attention to the gapping stocks in Friday's session. - ChartMill
Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NYSE:CANF) Stock Quote - FinancialContent
Can-Fite BioPharma stock rating downgraded to Hold by D. Boral Capital - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket - Sahm
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Sahm
NYSE AMEX Composite Index (XAX) - Investing.com Canada
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split By Investing.com - Investing.com South Africa
Can Fite Biopharma stock tumbles after announcing 1-for-3,000 reverse split - Investing.com India
Can-Fite BioPharma announces 1-for-3,000 reverse stock split - Investing.com
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change - Sahm
Can Can Fite Biopharma Ltd Sponsored ADR stock ride next bull market cycleMarket Rally & Community Verified Trade Signals - Улправда
EBITDA per share of Can-Fite BioPharma Ltd. Sponsored ADR – AMEX:CANF - TradingView — Track All Markets
AST SpaceMobile Inc (ASTS) can make a big difference with a little luck - setenews.com
Can Can Fite Biopharma Ltd Sponsored ADR stock survive global slowdown2025 Price Momentum & AI Based Trade Execution Alerts - Newser
Will Can Fite Biopharma Ltd Sponsored ADR stock see insider accumulation2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock sustain breakout momentum2025 Investor Takeaways & Expert Approved Momentum Ideas - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock test all time highsMarket Performance Report & Free Expert Approved Momentum Trade Ideas - Newser
How big funds are accumulating Can Fite Biopharma Ltd Sponsored ADR stockDividend Hike & AI Enhanced Trade Execution Alerts - Newser
Is Can Fite Biopharma Ltd Sponsored ADR stock positioned for secular growth2025 Key Lessons & Growth Focused Entry Reports - Newser
Can Can Fite Biopharma Ltd Sponsored ADR stock deliver double digit returnsJuly 2025 Short Interest & Fast Moving Stock Watchlists - Newser
Can-Fite Biopharma Ltd ADR Azioni (CANF) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):